Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World
Open Access
- 20 May 2014
- journal article
- clinical trial
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-12
- https://doi.org/10.1155/2014/528105
Abstract
Objective. To compare, “in a real world,” the performance of the most common composite activity indices in a cohort of PsA patients.Methods. A total of 171 PsA patients were involved. The following variables were evaluated: peripheral joint assessment, patient reported of pain, physician and patient assessments of disease activity, patient general health status, dactylitis digit count, Leeds Enthesitis Index, Health Assessment Questionnaire (HAQ), physical and mental component summary score of the Medical Outcome Survey (SF-36), Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). To measure the disease activity, the Disease Activity Score (DAS28-ESR and DAS28-CRP), Simple Disease Activity Index (SDAI), Composite Psoriatic Disease Activity Index (CPDAI), disease activity in psoriatic arthritis (DAPSA), and Psoriatic Arthritis Disease Activity Score (PASDAS) have been calculated. The criteria for minimal disease activity (MDA) and remission were applied as external criterion.Results. The ROC were similar in all the composite measures. Only the CPDAI showed less discriminative ability. There was a high degree of correlation between all the indices (). The highest correlations were between DAPSA and SDAI (rho = 0.996) and between DAPSA and DAS28-CRP (rho = 0.957). CPDAI, DAPSA, and PASDAS had the most stringent definitions of remission and MDA category. DAS28-ESR and DAS28-CRP had the highest proportions in remission and MDA.Conclusions. Although a good concurrent validity and discriminant capacity of six disease activity indices were observed, the proportions of patients classified in the disease activity levels differed. In particular, the rate of patients in remission was clearly different among the respective indices.
This publication has 45 references indexed in Scilit:
- Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trialBMJ, 2010
- The prevalence of psoriatic arthritis in people with psoriasisArthritis Care & Research, 2009
- Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritisAnnals Of The Rheumatic Diseases, 2009
- Erythrocyte Sedimentation Rate, C-Reactive Protein, or Rheumatoid Factor Are Normal at Presentation in 35%–45% of Patients with Rheumatoid Arthritis Seen Between 1980 and 2004: Analyses from Finland and the United StatesThe Journal of Rheumatology, 2009
- The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy peopleHealth and Quality of Life Outcomes, 2009
- Treatment recommendations for psoriatic arthritisAnnals Of The Rheumatic Diseases, 2008
- Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitisAnnals Of The Rheumatic Diseases, 2008
- Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritisArthritis Care & Research, 2008
- Outcome measures in psoriatic arthritis.2007
- Consensus on a core set of domains for psoriatic arthritis.2007